

## Rectal Clinical Trials

To go back to the main page, click [here](#)

S.No	Drug Name	Biological Name	Developer	Current Development Phase	Additional Information	Start Date	Completion Date	Source
11	-	carcinoembryonic antigen RNA-pulsed DC cancer vaccine	Duke University, National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment.	2000	2009	<a href="#">Source</a>
12	-	carcinoembryonic antigen RNA-pulsed DC cancer vaccine	Duke University, National Cancer Institute (NCI)	I/II	Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer.	1999	2009	<a href="#">Source</a>
13	-	QS21, ras peptide cancer vaccine	Fox Chase Cancer Center, National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of vaccine therapy plus QS21 in treating patients who have advanced pancreatic or colorectal cancer.	-	-	<a href="#">Source</a>
14	GI-4000	-	GlobelImmune	II	The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time	2010	2013	<a href="#">Source</a>
15	-	Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated	Hadassah Medical Organization	I/II	This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer	-	-	<a href="#">Source</a>
16	Endoxana, Leukine, IMA910, Aldara	-	Immatics Biotechnologies GmbH	I/II	This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients with advanced CRC to warrant further development	2008	2012	<a href="#">Source</a>
17	-	PSMA/PRAE	MannKind Corporation	I	Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.	2007	2009	<a href="#">Source</a>
18	MEDI-547	-	MedImmune/Anza	I	Terminated. Purpose was: To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory	2009	2010	<a href="#">Source</a>

					solid tumors			
19	-	V930 /V932	Merck	I	Completed. Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens	2007	2009	<a href="#">Source</a>
20	-	V934/V935	Merck	I	Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.	2008	2011	<a href="#">Source</a>
21	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	<a href="#">Source</a>
22	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	<a href="#">Source</a>
23	-	Interleukin-2	National Cancer Institute (NCI)	II	Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cancer.	-	-	-
24	-	Aldesleukin, ras peptide cancer vaccine	National Cancer Institute (NCI)	I/II	Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer.	1999	Ongoing	<a href="#">Source</a>
25	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	<a href="#">Source</a>
26	Detox-B adjuvant, ras peptide cancer vaccine	-	National Cancer Institute (NCI)	I	Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.	1995	Ongoing	<a href="#">Source</a>
27	-	ONT-10	Oncothyreon	Preclinical	-	-	-	-
28	Interferon-alpha	Trovax	Oxford BioMedica	II	Study has been completed	2006	2008	<a href="#">Source</a>
29	-	AdhTAP	TapImmune	Preclinical	-	-	-	-
30	-	OncoVAX autologous vaccine	Vaccinogen	III	Available in Netherlands/Switzerland Possible U.S. and E.U. approvals in 2014	-	-	-
31	-	CEA DNA Cancer Vaccine	Vical/Merck	I	The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.	2007	2009	-

To go back to the main page, click [here](#)